The WWOX (WW domain-containing oxidoreductase) antibody is a critical tool for studying the WWOX protein, encoded by the *WWOX* gene located on chromosome 16q23.3-24.1. This genomic region is frequently altered in cancers, particularly breast, ovarian, and lung cancers, due to chromosomal instability. WWOX is classified as a tumor suppressor, involved in regulating apoptosis, metabolism, and genomic stability. Its protein structure includes two WW domains, which mediate protein-protein interactions, and a short-chain dehydrogenase/reductase (SDR) domain, suggesting roles in steroid metabolism and redox signaling.
WWOX antibodies are widely used in research to detect WWOX expression levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Loss of WWOX expression, often linked to cancer progression or neurodegenerative disorders, is a key focus. Studies using these antibodies have revealed WWOX’s interactions with p53. AP-1. and other signaling molecules, highlighting its role in suppressing oncogenic pathways. Additionally, WWOX dysregulation is implicated in Alzheimer’s and epilepsy, broadening its relevance beyond oncology.
Despite its significance, WWOX antibody specificity can vary between clones, requiring careful validation for experimental applications. Research continues to explore WWOX’s dual roles in cancer suppression and neural function, driven partly by antibody-based investigations into its tissue-specific expression and post-translational modifications.